PubMed Health⌕ Search

Biomedical subjects

H Vahrson

Publications and source records attributed to H Vahrson.

At least 19 recordsLinked to original sources
PubMed1992

[Significance of determination of squamous cell carcinoma antigen in the follow up of patients with cancer of the uterine cervix].

The serum concentrations of squamous cell carcinoma antigen (SCC) were determined in 59 patients with invasive carcinoma of the uterine cervix, in 21 patients with benign cervical diseases. Pretherapeutic SCC levels were elevated (> 2.5 ng/ml) in 63% (34/54) of the patients with squamous cervical carcinoma. 5 patients with adenomatosus cervical carcinoma had not elevated levels. In 21 patients with benign cervical diseases, 4.8% (1/21) of SCC values were above the normal range. There were no correlation of SCC levels and the degree of the histological differentiation or clinical stages. Serial SCC determinations revealed a correlation with the clinical course of disease in 72.2% (26/36) with squamous cervical carcinoma. Rising levels were always associated with progression. The SCC level increased before clinical signs of progression with a median lead time of 3 months. Patients with cervical adenocarcinoma for follow up CA 125 determination was recommended. The determination of SCC is a useful tool checking the patients, detecting early progression of squamous cervical tumor.

Adenocarcinoma↗
PubMed1991

Initial experience with placental protein 4 (PP-4) as tumor marker in cervical and endometrial cancer.

PP-4, a recently characterized glycoprotein from human placenta was studied using a specific double-antibody radioimmunoassay in sera of 130 volunteers, 74 cervical cancer patients and 43 endometrial cancer patients. Elevated levels (greater than 3 micrograms/l) were found in 35 (47.3%) cervical cancer patients and in 18 (41.9%) endometrial cancer patients. Degree of elevation were not correlated with clinical stage, histology, and histological degree of differentiation. 36 patients with cervical cancer and 20 patients with endometrial cancer were monitored on two to seven occasions during four to 50 weeks. Rising, remaining unchanged of falling levels of PP-4 correlated with progression, stabilization or regression of disease 55.5% in patients with cervical and 65.0% in patients with endometrial cancer. During and some months after external telecobalt irradiation therapy wide range of PP-4 levels were observed in some patients. The study suggest that PP-4 can be regarded as a tumor associated protein which most likely can serve as tumor marker in cervical and endometrial cancer.

Annexin A5↗
PubMed1991

[Immunologic studies in patients with ovarian carcinoma during radio-chemotherapy. I. Studies of lymphocyte subpopulations].

In this article we have studied the behaviours of different lymphocyte subpopulations (T11, T8, T4, B4 and B1) in the peripheral blood of 60 patients suffering from ovarian cancer during radio- and chemotherapy with the APAAP-technique. The most important results of our study are that compared with the chemotherapy the radiotherapy causes greater lymphocyte depression, that the subpopulations of T-lymphocyte with the exception of T8 show greater radio-sensitivities than B-lymphocyte, that T8-subpopulation is not radio-sensitive, and that the T11-, T4-, B4- and B1-subpopulations of the patients at stage I and II can recover from the depression caused by radiation much better than the corresponding subpopulations of the patients at stage III and IV.

Adult↗
PubMed1987

[Primary cancer of Bartholin's gland].

Carcinoma of Bartholin's gland is an extremely rare tumour representing approximately between 1% and 7% of the cases of cancer of the vulva. The aetiology of the tumour, which can be subdivided by means of light microscopy into squamous cell carcinoma, adenocarcinoma, adenoid cystic carcinoma and adenoacanthoma, remains unknown. Surgical and radiotherapeutic treatment is possible also in combination. If primary operative therapy is chosen, inguinal lymphadenectomy is required as usually suggested in all cases of cancer of the vulva; the metastatic involvement of the inguinal lymph nodes is regarded as the main prognostic determinant: if only one inguinal node has microscopic metastases, a five-year survival rate between 60% and 70% can be achieved in a selected operative group of patients. If more than four positive groin nodes are histologically diagnosed the survival rate - according to current results, not subdivided into different alternatives of therapy - is below 20%.

Adenocarcinoma↗
PubMed1985

[Hysterography with afterloading-applicator in place. A simple method for improving the treatment planning of uterine cancer].

Anatomical configurations often are an obstacle to a convenient dose-distribution in intracavitary afterloading irradiation. Multiple applicators (splay applicators, twin applicators) cannot be introduced in all cases because of the necessary cervix dilatation. In several cases can be demonstrated, that a defined intracavitary irradiation is possible only by hysterographic control of the intrauterine position of the applicator. By this control generally a mono-applicator is sufficient, which can be placed according the anatomy of the uterine cavity in each session. For this purpose a simple hysterographic method with applicator in position is demonstrated, which requires only few additional effort during intracavitary irradiation.

Aged↗
PubMed1983

[After care of ovarian carcinoma from gynecologic viewpoint].

A co-operation between the different institutions and doctors and the tumor centre is indispensable for an adequate follow-up of the ovarial carcinoma. Besides diagnosis and therapy of side effects of the treatment as well as early diagnosis of recurrences, a psychical and social care is particularly necessary. The follow-up treatment aims at a full social rehabilitation of probably cured patients and, in case of incurable patients, at a relief of pain until death. The determination of t-RNA as a reliable tumor marker and the examinations necessary for routine controls (minimal and maximal programme) are indicated.

Aftercare↗
PubMed1980

alpha-Fetoprotein, carcinoembryonic antigen, human chorionic gonadotropin and its beta subunit in metastatic choriocarcinoma: short-term follow-up and determinations of resistance during chemotherapy.

Serum levels of alpha fetoprotein (AFP), carcinoembryonic antigen (CEA), human chorionic gonadotropin (hCG) and its beta subunit (beta-hCG) were measured during the therapy of a choriocarcinoma with lung metastases. All AFP determinations were in the normal range. The CEA levels showed a correlation with the radiologically confirmed development of lung metastases. A rise of hCG during the first 2--6 days to 177.3--407.5% of the initial level and a descent to 17.9--33.7% of the initial level at the 10th day of therapy were typical behavioral patterns associated with tumor sensitivity. The onset of tumor resistance against the chemotherapeutic preparation used was evident within 10 days after therapy. A small rise, a slight fall below the initial value, and then a rapid increase to above the initial level were typical parameters. With established tumor resistance there was an autonomous unremitting increase of hCG activity. Short-term follow-up to hCG in intervals of 2 days at least for over a period of 10 days are deemed advisable for early detection of resistance toward the particular chemotherapeutic preparation used.

Adult↗
PubMed1980

[Effect of colloidal 198Au on cell cultures of human tumors (author's transl)].

The authors observed the effect of colloidal 198Au on the morphology of cells in 19 cell cultures of human tumors. Partly, there were typical modifications. The reactions of the individual cells were different and the radiosensibility and dependence on the dose seemed to vary with different concentrations of the radiogold. The importance of this study with regard to clinical problems is discussed.

Cells, Cultured↗
PubMed1979

[Alterations of the plasma ribonuclease activity in female wistar rats under the conditions of combined therapy of the ovary carcinoma (author's transl)].

The authors have analysed the influence exercised by the combined therapy of the ovary carcinoma on the plasma ribonuclease activity in Wistar rats. The medicaments "Proresid", "VM-26", and "Methotrexat" together with a percutaneous irradiation of the abdomen did not alterate perceptibly the enzyme activity during the experiment, but there was a considerable reduction of the enzyme activity after an application of "Endoxan", "Adriblastin" and "Methotrexat" with subsequent administration of "Leukovorin". The most violent ribonuclease suppression, however, was obtained by an intraperitoneal instillation of radiogold and a fractioned percutaneous irradiation of the abdomen with intercalated administration of "Endoxan".

Animals↗
PubMed1979

[Determination of the plasma ribonuclease activity as a diagnostic aid in the diagnosis of ovarian cancer. Results of a double blind study (author's transl)].

The determination of the plasmaribonucleases was reported by Sheid and co-workers in 1977 for the diagnosis of carcinoma of the ovary. The authors investigated the accuracy of this test with a modified method in a double blind study encompassing healthy controls. Blood samples from 62 patients with ovarian cancer were tested. The results were accurate in 56 cases. In 6 cases the test results were doubtful. The difference in the ribonuclease activity was significant between patients with ovarian cancer and healthy patients or patients in remission from ovarian cancer. The results were not dependant upon the FIGO staging of the disease. Our results encourage the recommendation to use this test as a diagnostic aid in carcinoma of the ovary.

Clinical Enzyme Tests↗
PubMed1977

[The toxicity of massive dosis of VM26 (4-demethyl-epipodophyllotoxin-beta-D-thenylidene glucoside). A contribution to the therapy of advanced ovarian cancer (author's transl)].

19 patients with advanced ovarian cancer (FIGO-stages IIb-IV) were treated by ultra-high doses of VM26 partly according to positive oncobiograms during Multiple-drug-stoss-therapy. The toxic reactions and the cytostatic effect were investigated. The range of 57,9% remissions and the moderate toxicity suggest a specific application of VM26 in advanced ovarian cancer.

Aged↗